The global prinzmetal angina therapeutics market is expected to surpass an impressive valuation of US$ 10.7 Billion in 2023 and is projected to reach US$ 17.2 Billion by 2033, trailing a CAGR of 4.85%. The development of biosimilars and biobetters, growth in diabetic and hypertension population due to unhealthy lifestyle and rise in consumption of alcohol and …
Monthly Archives: February 2023
Cytokine Release Syndrome Management Market is expected to be worth US$ 44.6 billion by 2033 | FMI Analyst
The global Cytokine Release Syndrome Management Market is expected to be worth US$ 23.32 billion in 2023, growing at a 6.7% CAGR between 2023 and 2033. In the coming years, the market for CRS management is expected to grow due to an increase in the number of autoimmune diseases and cancers. The development of novel …
Pituitary Stalk Interruption Syndrome Treatment Market value of US$ 112.82 Million in 2023
During the forecast period 2023-2033, the pituitary stalk interruption syndrome treatment market is expected to grow at a value of 3.5% CAGR, according to Future Market Insights. By the year 2033, the global market for pituitary stalk interruption syndrome treatment is expected to rise up to a market valuation of US$ 159.14 Million. Growth of the pituitary …
Rheumatic-Heart Disease Management Market is expected to be valued at US$ 1.31 Billion in 2023
The global Rheumatic-Heart Disease Management market size is expected to be valued at US$ 1.31 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Rheumatic-Heart Disease Management is projected to grow at a CAGR of 4.5% between 2023 and 2033, totaling around US$ 2.04 Billion by 2033. The rising prevalence of cardiovascular diseases globally is one of the major …
Heterozygous Familial Hypercholesterolemia (HEFH) Management Market reaching a value of US$ 58.54 Billion by 2033
In fiscal year 2023, the market for managing heterozygous familial hypercholesterolemia (HEFH) management is anticipated to be valued US$ 15.11 Billion, up from US$ 13.2 billion in fiscal year 2022. The worldwide market is anticipated to expand at a constant 14.5% CAGR from 2023 to 2033, reaching a value of US$ 58.54 Billion by the end of …
Fucosidosis Therapeutics Market is expected to reach US$ 17.91 Million by 2033 | FMI Study
The global Fucosidosis Therapeutics Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Fucosidosis Therapeutics registered a CAGR of 4% in the …
Idiopathic Pulmonary Fibrosis Management Market is expected to reach US$ 3649.90 Million by 2033 | FMI
The global Idiopathic Pulmonary Fibrosis Management Market is expected to generate a market value of US$ 3145 Million in 2023 and a market value of US$ 3649.90 Million by 2033, with a CAGR of 1.5% from 2023 to 2033. The increasing prevalence of the disease in males around the world has contributed to the growth …
The Global Encephalitis Treatment Market Is Expected to Register Growth at 5.4% CAGR through 2033 | FMI Study
The global Encephalitis Treatment Market is currently valued at US$ 20.14 billion in 2023, with a CAGR of 5.4% expected. Because of technological advancements in healthcare, the market is expected to reach US$ 34.08 billion by 2033. The major factor attributing to the growth of the market is the high mortality and morbidity rate caused …
Cardiovascular Ultrasound Market is expected to reach a US$ 2.6 billion valuation by 2033 | FMI Study
The Cardiovascular Ultrasound Market revenues were estimated at US$ 1.2 Billion in 2021 and is anticipated to grow at a CAGR of 7.2% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 2.6 Billion. The market is predicted to grow as …
Liver Fibrosis Treatment Market to surge at an 11% CAGR until 2033, reaching US$ 46.65 billion | FMI Study
The global Liver Fibrosis Treatment Market is anticipated to exceed a remarkable valuation of US$ 16.43 billion in 2023, with a compound annual growth rate (CAGR) of 11% projected from 2023 to 2033. The rising prevalence of undesirable outcomes such as hepatitis B or C virus infection, an impaired immune system due to co-infection with …